Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Non-small Cell Lung Cancer (NSCLC)
Clinical trial register · United States · industry-sponsored

Non-small Cell Lung Cancer (NSCLC) Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9141 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 18 Oct 2026, 03:16 UTC
9141
Studies in scope
industry-sponsored, all four open statuses
4966
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 30 Florida 27 Texas 18 New York 16 Massachusetts 15
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Revolution Medicines, Inc.8 Bristol-Myers Squibb5 Merck Sharp & Dohme LLC3 AstraZeneca3 Daiichi Sankyo2
State
California30 Florida27 Texas18 New York16 Massachusetts15
All 41 states
Target enrolment
to

Non-small Cell Lung Cancer (NSCLC) trials in the USA

45 of 9141 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Pfizer
Phase 1
80
Illinois, Texas
2026-10-23
Recruiting
Revolution Medicines, Inc.
Phase 3
430
Florida
2026-08-14
Recruiting
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
NCT07660055Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
Novartis Pharmaceuticals
Phase 1
156
Nebraska
2026-06-16
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
California, New Jersey, Texas, Virginia
2026-04-28
Recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT07540572ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
DrugFulvestrant
IDEAYA Biosciences
Phase 1
160
Florida, New Jersey, New York, Texas, Utah, Virginia
2026-03-17
Recruiting
Bristol-Myers Squibb
Phase 3
850
Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
750
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-12
Recruiting
Genmab
Phase 2
240
California, District of Columbia, Florida, Georgia, Montana, Nebraska, New Jersey, New York
2026-01-30
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
DrugsElironrasib·Zoldonrasib·Ivonescimab·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
370
California, Connecticut, Minnesota, Tennessee, Texas, Virginia
2026-01-30
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 1
574
Connecticut, Maryland, Massachusetts, Michigan, New York, Texas, Virginia
2026-01-08
Recruiting
Integro Theranostics
Phase 2
35
Pennsylvania, Texas
2025-12-08
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
DrugsCetuximab·Nab-paclitaxel·Gemcitabine·Pembrolizumab
Bristol-Myers Squibb
Phase 1/2
252
Maryland, Texas, Utah, Virginia
2025-11-25
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Massachusetts, New York, Texas, Virginia
2025-11-07
Recruiting
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois
2025-10-31
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
DrugGilteritinib
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Recruiting
Nuvation Bio Inc.
Phase 3
180
California, District of Columbia, Florida, Idaho, Louisiana, Massachusetts, Minnesota, New York
2025-08-21
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
Tanabe Pharma America, Inc.
Phase 1/2
27
California, Michigan, Ohio, Texas
2025-04-18
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
California, District of Columbia, Florida, South Carolina, Tennessee, Texas, Virginia
2025-01-29
Active, closed
Bristol-Myers Squibb
Observational
300
Florida
2024-11-22
Recruiting
Pierre Fabre Medicament
Phase 1/2
171
Tennessee, Texas
2024-09-17
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 1
240
California, New Jersey, Ohio, Texas
2024-09-06
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
102
Michigan, Ohio
2024-08-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
California, Florida, Georgia, Michigan, Missouri, New Jersey, New York, North Dakota
2024-06-11
Recruiting
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
NCT06332755Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma
LG Chem
Phase 1
76
Virginia
2024-06-05
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Michigan, Montana
2024-01-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Arizona, California, Colorado, Florida, Georgia, Kentucky, Maine, Massachusetts
2023-12-15
Recruiting
Amgen
Phase 3
750
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, New Mexico, New York
2023-11-16
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
California, Colorado, Florida, Indiana, Massachusetts, Michigan, New York, Oklahoma
2023-11-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
California, Florida, Georgia, Michigan, Minnesota, Mississippi, Nebraska, New Jersey
2023-11-12
Active, closed
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
NCT05799274Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
Radiopharm Theranostics, Ltd
Phase 1
9
New Jersey, New York
2023-11-09
Recruiting
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
DrugsAdagrasib·Cabozantinib
Kura Oncology, Inc.
Phase 1
300
Arizona, California, Colorado, Florida, Iowa, Massachusetts, Michigan, Minnesota
2023-10-18
Recruiting
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
DrugsRMC-9805·Cetuximab
Revolution Medicines, Inc.
Phase 1
604
California, Connecticut, Florida, Maryland, Massachusetts, New York, North Carolina, Ohio
2023-09-07
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1/2
230
California, Michigan, New York, Ohio, Texas, Utah
2023-07-06
Active, closed
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
NCT05585320Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
DrugsModified FOLFIRINOX·Dabrafenib·Pembrolizumab
Immuneering Corporation
Phase 1/2
209
Arizona, California, Colorado, Florida, Illinois, Massachusetts, Minnesota, New York
2022-10-31
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
DrugElironrasib
Revolution Medicines, Inc.
Phase 1
222
Arkansas, California, Florida, Maryland, Massachusetts, New York, Tennessee, Texas
2022-09-19
Active, closed
ArriVent BioPharma, Inc.
Phase 1
160
Arizona, California, Florida, Michigan, Texas, Virginia
2022-06-30
Recruiting
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
DrugCetuximab
Revolution Medicines, Inc.
Phase 1/2
754
California, Florida, Georgia, Louisiana, Maryland, Massachusetts, New York, Ohio
2022-05-31
Active, closed
Daiichi Sankyo
Phase 1
246
California, Connecticut, District of Columbia, Illinois, Massachusetts, Michigan, New Hampshire, New York
2021-06-11
Active, closed
AbbVie
Phase 1
81
Massachusetts, Missouri, North Carolina, Rhode Island, Texas, Virginia
2021-02-23
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Alaska, California, Connecticut, Delaware, Florida, Illinois, Kentucky, Maryland
2019-09-17
Active, closed
AbbVie
Phase 1
150
Arkansas, California, Connecticut, Florida, Indiana, Missouri, North Carolina, Pennsylvania
2019-05-21
Active, closed
AstraZeneca
Phase 2
401
Florida, Missouri, Pennsylvania, Tennessee, Texas
2018-12-21
Active, closed
Daiichi Sankyo
Phase 1
312
California, Georgia, Massachusetts, Michigan, New York, Ohio, Pennsylvania, Tennessee
2017-10-30
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab
Replimune, Inc.
Phase 2
340
Alabama, Arizona, Arkansas, California, Florida, Iowa, Kentucky, Minnesota
2017-09-20
Active, closed
AstraZeneca
Phase 3
1,186
Arizona, California, Florida, Kentucky, Missouri, Ohio, Pennsylvania, Tennessee
2017-06-01
Rows per page Showing 1–45 of 45
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/non-small-cell-lung-cancer-nsclc

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,141 studies in total at the last sync on 18 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 45 of those studies listing the condition Non-small Cell Lung Cancer (NSCLC).

How many Non-small Cell Lung Cancer (NSCLC) trials are recruiting in the US?

27 of the 45 studies on this page are recruiting new participants as of the 18 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Non-small Cell Lung Cancer (NSCLC)), 45 studies
PhaseStudiesRecruitingShare
Phase 117937.8%
Phase 1/212826.7%
Phase 311824.4%
Phase 2428.9%
Observational102.2%

Most active sponsors

Lead sponsors with the most studies (Non-small Cell Lung Cancer (NSCLC))
Lead sponsorStudiesRecruiting
Revolution Medicines, Inc.87
Bristol-Myers Squibb54
AstraZeneca31
Merck Sharp & Dohme LLC31
AbbVie20
Astellas Pharma Global Development, Inc.22
Daiichi Sankyo20
Genmab21
Amgen11
ArriVent BioPharma, Inc.10

Top states

Top states (Non-small Cell Lung Cancer (NSCLC)), by number of studies with a site there
StateStudies
California30
Florida27
Texas18
New York16
Massachusetts15
Michigan13
Colorado10
Georgia10
Virginia10
Arizona9
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.